| DGX |
Report |
Adjusted Diluted EPS (Q2 2026) |
BEAT |
pred ~$2.88 vs. cons $2.82 |
MEDIUM |
| DGX |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$3.01B vs. cons $2.98B |
MEDIUM |
| DGX |
Report |
Organic Revenue/Volume Growth (Q2 2026) |
BEAT |
pred ~9.0% organic growth vs. cons/implied ~8.0% |
MEDIUM |
| DGX |
Guide |
FY2026 Adjusted EPS Guidance |
BETTER |
guide ~$10.85 (raised range midpoint) vs. cons $10.72 (FY2026) |
MEDIUM |
| DGX |
Guide |
FY2026 Revenue Guidance |
BETTER |
guide ~$11.90B (raised range midpoint) vs. cons $11.83B (FY2026) |
MEDIUM |
| DGX |
Guide |
H2 Cost Headwinds (Project Nova dilution/fuel/weather commentary) |
UNCHANGED |
guide ~$0.25 EPS dilution from Nova (60%+ in H2) vs. prior guided ~$0.25 already embedded (H2 2026) |
LOW |
| DGX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| DGX |
Return |
5-day cumulative residual |
+0.3% (FADE) |
Consensus already assumes another beat-and-raise given DGX's 4-quarter beat streak and Q1 blowout, and shares sit near 52-week highs (~23x fwd EPS) after a 24.5% YTD run, so an in-line-to-modest beat is largely priced in, capping the initial pop. More importantly, management has explicitly guided H2 EPS/revenue phasing lower (just over 50% of FY EPS in H2 vs ~49% H1) due to Project Nova spend (>60% loaded into H2, ~$0.25 dilution), elevated fuel costs, and a tougher weather comp versus 2025's unusually mild season — these are real, quantified out-period drags that analysts will bake into H2/FY27 revisions even if Q2 itself beats and FY26 guidance is nudged up. That combination (priced-for-perfection setup + known H2 cost step-up + tougher YoY comps on Corewell/Fresenius contribution) points to an initial positive reaction fading over the following days as the buy-side digests the implicit margin deceleration into H2, rather than sustained follow-through. |
MEDIUM |